Daily News

Daily News

iPSCs: A preclinical drug research tool for neurological disorders

Stem Cell Daily

2021 MAY 06 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Daily -- Fresh data on molecular science are presented in a new report. According to news originating from Catania, Italy, by NewsRx correspondents, research stated, “The development and commercialization of new drugs is an articulated, lengthy, and very expensive process that proceeds through several steps, starting from target identification, screening new leading compounds for testing in preclinical studies, and subsequently in clinical trials to reach the final approval for therapeutic use.”

The news editors obtained a quote from the research from Italian National Research Council: “Preclinical studies are usually performed using both cell cultures and animal models, although they do not completely resume the complexity of human diseases, in particular neurodegenerative conditions. To this regard, stem cells represent a powerful tool in all steps of drug discovery. The recent advancement in induced Pluripotent Stem Cells (iPSCs) technology has opened the possibility to obtain patient-specific disease models for drug screening and development.”

According to the news editors, the research concluded: “Here, we report the use of iPSCs as a disease model for drug development in the contest of neurological disorders, including Alzheimer’s (AD) and Parkinson’s disease (PD), Amyotrophic lateral Sclerosis (ALS), and Fragile X syndrome (FRAX).”

For more information on this research see: iPSCs: A Preclinical Drug Research Tool for Neurological Disorders. International Journal of Molecular Sciences, 2021,22(4596):4596. (International Journal of Molecular Sciences - http://www.mdpi.com/journal/ijms). The publisher for International Journal of Molecular Sciences is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/ijms22094596.

Our news journalists report that additional information may be obtained by contacting Gabriele Bonaventura, Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy. Additional authors for this research include Rosario Iemmolo, Giuseppe Antonino Attaguile, Valentina La Cognata, Brigida Sabrina Pistone, Giuseppe Raudino, Velia D’Agata, Giuseppina Cantarella, Maria Luisa Barcellona, Sebastiano Cavallaro.

(Our reports deliver fact-based news of research and discoveries from around the world.)